Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6205MR)

This product GTTS-WQ6205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6205MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ3432MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ12525MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ14010MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ618MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ4903MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ5646MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ13943MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW